-- New AMRI Drug Discovery Center to Enable Translational
Research Platforms
BUFFALO, New York, June 17, 2015 /PRNewswire/ -- As further evidence
of Governor Andrew M. Cuomo's
successful establishment of a dynamic and growing bio-pharma sector
in Buffalo, New York, Albany
Molecular Research Inc. (NASDAQ: AMRI) and PerkinElmer, Inc. today
announced the formation of a strategic collaboration in connection
with the opening of AMRI's drug discovery center as part of the new
Buffalo Medical Innovation and Commercialization Hub (BMIC).
Co-located on the Buffalo Niagara Medical Campus and part of the
larger commitment by the State of New
York with SUNY Polytechnic Institute, the Hub will
accelerate drug discovery and innovation, and ultimately support
the creation of more than 250 high tech jobs.
As the anchor partner of the BMIC Hub, AMRI is able to provide
integrated and translational approaches, including the deep
expertise and capabilities required to move drug development
programs from early discovery to the clinic. Located all within a
single site on the Buffalo Niagara Medical Campus, AMRI will be
working closely with BMIC and off-campus customers and partners to
provide solutions for their drug discovery and translational
science needs. Scientists at the BMIC hub will be able to leverage
AMRI's chemistry and biology expertise, alongside PerkinElmer's
informatics technologies and high content screening, cellular
imaging, and analytical instruments. PerkinElmer will also deploy
technical and informatics experts to facilitate technological and
drug discovery innovations. The collaboration will also provide the
foundation for new research and development opportunities and
catalyze the expansion of the BMIC hub.
"We are delighted to work together on this unique public-private
endeavor with PerkinElmer, which is recognized in the industry for
its leading drug discovery technologies and informatics platforms,
that are critical for the success of AMRI's Discovery and
Development businesses," said Dr. Michael
A. Luther, Senior Vice President, Discovery and Development,
AMRI. "PerkinElmer's technologies will provide us with the ability
to acquire, manage, integrate and analyze large complex data from
the various translational platforms needed to drive better
decisions in drug discovery. This will enable us to accelerate the
knowledge and information our customers and partners need and
strengthen our end-to-end integrated discovery offerings."
"We are pleased to have the opportunity to deliver the
platforms, informatics technologies and services to AMRI for its
new center of excellence for drug discovery and translational
research," said Jim Corbett,
President, Human Health, PerkinElmer. "We look forward to
supporting the BMIC's expansion by working closely with additional
companies that establish lab facilities at this site, providing
scientists with solutions and services that will advance their
research and lead them toward the next big breakthrough."
"Industry collaborations are a natural outgrowth of Governor
Cuomo's innovation-driven economic development strategy, and the
result is rapid job creation in Western
New York and increased opportunities for ground-breaking
breakthroughs," said SUNY Poly Vice President for Research Dr.
Michael Liehr. "These types of
strategic relationships will serve as a magnet for bringing other
global partners and jobs to Buffalo and build the foundation for
additional collaborations, including cross-sector opportunities
with our IT and green energy hubs."
About AMRI. Albany Molecular Research Inc. (AMRI) is a
global contract research and manufacturing organization that has
been working with the Life Sciences industry to improve patient
outcomes and the quality of life for more than two decades. With
locations in North America,
Europe and Asia, our key business segments include
Discovery and Development Services (DDS), Active Pharmaceutical
Ingredients (API) and Drug Product Manufacturing. Our DDS segment
provides comprehensive services from hit identification to IND,
including expertise with diverse chemistry, library design and
synthesis, in vitro biology and pharmacology, drug
metabolism and pharmacokinetics, as well as natural products. API
Manufacturing supports the chemical development and cGMP
manufacture of complex API, including potent, controlled
substances, biologics, peptides, steroids and cytotoxic compounds.
Drug Product Manufacturing supports drug product development
through commercial scale production of complex liquid-filled and
lyophilized parenteral formulations. For more information about
AMRI, please visit our website at www.amriglobal.com or follow us
on Twitter (@amriglobal).
About PerkinElmer. PerkinElmer, Inc. is a global leader
focused on improving the health and safety of people and the
environment. The Company reported revenue of approximately
$2.2 billion in 2014, has about 7,700
employees serving customers in more than 150 countries, and is a
component of the S&P 500 Index. Additional information is
available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
About the BMIC Hub. The Buffalo Medical Innovation and
Commercialization Hub (the "BMIC Hub") at Buffalo Niagara Medical
Campus is a new public-private pharmaceutical research and
development initiative in Buffalo,
N.Y. announced by New York
Governor Andrew M. Cuomo in
December 2012. The BMIC Hub is a
collaboration that involves SUNY Polytechnic Institute and the
State of New York, AMRI, and other
industry partners to provide life science discovery services,
cutting-edge platforms and expertise to academia and industry from
early discovery to candidate selection and beyond.
SUNY Polytechnic Institute. SUNY Polytechnic Institute
(SUNY Poly) is New York's globally
recognized, high-tech educational ecosystem, formed from the merger
of the SUNY College of Nanoscale Science and Engineering and
SUNY Institute of Technology. SUNY Poly
offers undergraduate and graduate degrees in the emerging
disciplines of nanoscience and nanoengineering, as well as
cutting-edge nanobioscience and nanoeconomics programs at its
Albany location and undergraduate
and graduate degrees in technology, including engineering,
cybersecurity, computer science, and the engineering technologies;
professional studies, including business, communication, and
nursing; and arts and sciences, including natural sciences,
mathematics, humanities, and social sciences at its Utica/Rome
location. Thriving athletic, recreational, and cultural programs,
events, and activities complement the campus experience. As the
world's most advanced, university-driven research enterprise, SUNY
Poly boasts more than $20 billion in
high-tech investments, over 300 corporate partners, and maintains a
statewide footprint. The 1.3 million-square-foot Albany NanoTech
megaplex is home to more than 3,500 scientists, researchers,
engineers, students, faculty, and staff, in addition to Tech Valley
High School. SUNY Poly operates the
Smart Cities Technology Innovation Center (SCiTI) at Kiernan Plaza
in Albany, the Solar Energy
Development Center in Halfmoon,
the Central New York Hub for Emerging Nano Industries in
Syracuse, the Photovoltaic
Manufacturing and Technology Development Facility in Rochester, and the Smart System Technology and
Commercialization Center (STC) in Canandaigua. SUNY Poly founded and manages the
Computer Chip Commercialization Center (Quad-C) at its Utica location and also manages the
$500 million New York Power
Electronics Manufacturing Consortium, with nodes in Albany and Rochester, as well as the Buffalo High-Tech
Manufacturing Innovation Hub at RiverBend, Buffalo Information
Technologies Innovation and Commercialization Hub, and Buffalo
Medical Innovation and Commercialization Hub. For information:
visit www.sunycnse.com and www.sunypoly.edu.